Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 277
Selected: 0
NCT IDTitle
NCT02951195A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
NCT04167345Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
NCT05312879Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
NCT00621296Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
NCT00630058A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C
NCT01052194A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
NCT04969224A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)
NCT05535959A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor
NCT07074327Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
NCT01899105A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor
NCT00892697Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
NCT07010406A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations
NCT05437120Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment
NCT04599465A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)
NCT02445053Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)
NCT02141464Energy Balance and Weight Gain With Ivacaftor Treatment
NCT07378865Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
NCT05518734A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants
NCT03859531Gastrointestinal Study at Orkambi Therapy in CF Patients
NCT03338595Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF
NCT06619847A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
NCT02953314A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)
NCT02343445Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)
NCT05851157A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548
NCT01890772Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1
NCT01216046Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
NCT06619860Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT02392234A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
NCT01821963Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
NCT03525444A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT03163511A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
NCT03783286Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects
NCT02709109A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
NCT05477563Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT00953706Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
NCT03227471A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
NCT06312787A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation
NCT01253551VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir
NCT03764072A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
NCT03304028MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique
NCT06696443Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT01060566Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770
NCT01830985A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
NCT06861413A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
NCT02971839Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
NCT05882357Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age
NCT04006873Gut Imaging for Function & Transit in Cystic Fibrosis Study 2
NCT03655678A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
NCT05660538Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
NCT05867147An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants